Latest News

ServisFirst Bancshares (SFBS) capped FY 2025 with fourth quarter revenue of US$154.3 million and EPS of US$1.58, as trailing twelve month figures reached US$527.1 million in revenue and EPS of US$5.06. Over the past year, revenue has moved from US$458.7 million on a trailing basis to US$527.1 million, while EPS over the same period shifted from US$4.17 to US$5.06, providing additional context for how you might think about the bank’s earnings power. With a trailing net profit margin of 52.5%...

Charles Schwab FY 2025 Earnings Snapshot Charles Schwab (SCHW) closed FY 2025 with fourth quarter revenue of US$6.3 billion and basic EPS of US$1.34, alongside net income excluding extra items of US$2.4 billion, putting a solid set of headline numbers in front of investors. The company has seen quarterly revenue move from US$5.3 billion and EPS of US$0.94 in Q4 2024 to US$6.3 billion and EPS of US$1.34 in Q4 2025, alongside trailing twelve month EPS of US$4.67 and revenue of US$24.0 billion...

Earlier in January 2026, AtriCure issued 2026 revenue guidance of approximately US$600 million to US$610 million and amended its asset-based revolving credit facility, extending the term, lowering interest rates and maintaining up to US$125 million in borrowing capacity with the option to increase to US$165 million. Together, the higher revenue outlook and more flexible, lower-cost credit line highlight management’s confidence in AtriCure’s growth plans and liquidity position. Next, we’ll...

United Airlines FY 2025 Earnings Snapshot United Airlines Holdings (UAL) has wrapped up FY 2025 with Q4 revenue of US$15.4b and basic EPS of US$3.19, supported by net income of US$1,044m. Over recent quarters, the company has seen revenue move from US$14.7b in Q4 2024 to US$15.2b in Q3 2025 and US$15.4b in Q4 2025. Basic EPS over the same Q4 periods shifted from US$2.94 to US$3.19, setting up a results season where investors can weigh steady top line and earnings against how efficiently those...

Why Day One Biopharmaceuticals is in the spotlight Day One Biopharmaceuticals (DAWN) is back on investors’ radar after releasing preliminary 2025 OJEMDA revenue figures and issuing fresh 2026 guidance that ties directly to prescription and patient demand trends. The company reported unaudited OJEMDA net product revenue of approximately US$52.8 million for the fourth quarter of 2025 and US$155.4 million for the full year, with prescription volumes reaching 1,394 in the quarter. Management also...

In mid-January 2026, Sensata Technologies announced the launch of its STEV high-voltage contactor series, a scalable, customizable solution designed to improve safety, efficiency and integration across battery electric and plug-in hybrid vehicle platforms from passenger cars to heavy-duty trucks. A distinctive aspect of the STEV lineup is its combination of bidirectional current capability, hermetic ceramic sealing and global in-region manufacturing, positioning Sensata as a key enabler of...

Teledyne Technologies (TDY) has wrapped up FY 2025 with fourth quarter revenue of US$1.6b and basic EPS of US$5.60, alongside trailing twelve month revenue of US$6.1b and EPS of US$18.88 that frame the latest print in a broader earnings run. Over the past six quarters in the data, quarterly revenue has ranged from US$1.44b to US$1.61b, while basic EPS has moved between US$4.03 and US$5.61, giving investors a clear view of how the top and bottom lines have tracked together through recent...

If you are wondering whether Universal Technical Institute's share price still offers value after recent moves, it helps to step back and look at what the current market price might be implying. The stock last closed at US$28.15, with returns of 5.9% over the past week, 5.0% over the last month, 13.3% year to date, 6.1% over 1 year, and very large gains over 3 and 5 years. Recent attention on Universal Technical Institute has focused on its role in career and technical education, as...

Riverwater Partners recently highlighted IRADIMED CORPORATION as the top contributor to its Micro Opportunities Strategy in 2025, following record Q3 2025 revenue of US$21.2 million and FDA approval of the company’s MRI-compatible 3870 IV infusion pump in July 2025. Beyond the financial headlines, IRADIMED’s combination of accelerating revenue, new FDA-cleared technology and a special dividend, alongside insider share sales and a “Moderate Buy” analyst consensus, paints a complex picture of...

The board of Cardinal Energy Ltd. ( TSE:CJ ) has announced that it will pay a dividend on the 17th of February, with...

Industrias Peñoles. de's (BMV:PE&OLES) stock is up by a considerable 43% over the past three months. Since the market...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

As the Canadian market navigates a landscape filled with geopolitical tensions and U.S. policy shifts, fundamentals such as low energy prices, moderating inflation, and solid growth continue to underpin its stability. In this environment of broadening market leadership and resilience, identifying stocks that are trading below their fair value can offer potential opportunities for investors focused on strong economic and corporate fundamentals.

As the Canadian market navigates a landscape filled with geopolitical tensions and policy shifts, fundamentals such as low energy prices and moderating inflation continue to provide a stable foundation, allowing the TSX to reach record highs. In this environment, growth companies with high insider ownership can be particularly appealing, as they often signal confidence from those closest to the business and may benefit from resilient economic conditions.

The Canadian market has shown remarkable resilience, with the TSX reaching record highs despite a backdrop of geopolitical tensions and policy shifts. In such a stable economic climate, investors often look beyond the headlines to explore opportunities that may not be immediately apparent. Penny stocks, while sometimes perceived as outdated, continue to offer potential value and growth by focusing on smaller or newer companies with robust financials.

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...

If you are wondering whether Upbound Group's current share price reflects its underlying value, you are not alone. This article focuses squarely on what the numbers say about the stock. The share price closed at US$19.43, with a 9.7% gain over the last 30 days but a 29.4% decline over the past year. This raises questions about how the market is currently pricing the business and its risks. Recent news flow for Upbound Group has included ongoing commentary around the rent to own and lease to...

AbCellera Biologics (ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for menopausal vasomotor symptoms. See our latest analysis for AbCellera Biologics. The ABCL635 Phase 2 start comes as AbCellera’s 30 day share price return of 15.05% and year to date share price return of 24.78% contrast with a 3 year total shareholder return of 58.89% decline, suggesting sentiment has improved recently after a...

If you are wondering whether Newmark Group's share price still offers value after a long run on the market, this article breaks down what the current valuation implies for you as a shareholder or potential investor. Newmark Group's stock last closed at US$17.75, with returns of 5.7% over 7 days, 1.5% over 30 days, 4.6% year to date, 30.1% over 1 year and 113.0% over 3 years. These figures raise fair questions about how much of the story is already reflected in the price. Recent coverage has...

National Bank Financial recently upgraded RB Global (NYSE:RBA), highlighting market share gains and contract wins in Australia and the UK. The firm pointed to new agreements with Suncorp and Direct Line as key drivers of RB Global's expanding presence in vehicle and asset remarketing. The upgrade focuses on the company's growing international footprint and its potential to win additional business in core markets. RB Global runs auctions and related services that help businesses sell heavy...

Commerce Bancshares (NasdaqGS:CBSH) has closed its acquisition of FineMark National Bank & Trust. The deal expands Commerce's wealth management and private banking reach into Florida, Arizona, and South Carolina. FineMark will operate as a division within Commerce Bank while maintaining existing client relationships. For investors, this move adds more scale and breadth to Commerce Bancshares' long standing banking and wealth management franchise. Wealth management and private banking have...

Event context and recent stock performance Amicus Therapeutics (FOLD) has caught investor attention after a sharp share price move in the past 3 months, with the stock returning about 69% over that period. See our latest analysis for Amicus Therapeutics. That sharp 68.82% 90 day share price return sits alongside a 50.42% 1 year total shareholder return, while the 5 year total shareholder return of a 24.39% decline shows longer term holders have had a tougher journey, which suggests that...

Why Edenred’s New Bond Issue Matters for Shareholders Edenred (ENXTPA:EDEN) has just raised €500 million through a 7‑year bond at a 3.75% coupon, a funding move that drew strong institutional demand and was more than 3 times oversubscribed. The proceeds are earmarked for general corporate purposes, including refinancing an existing €500 million bond maturing in March 2026. This helps Edenred lengthen its debt maturity profile and support its Amplify25‑28 plan. See our latest analysis for...

Latest FY 2025 Earnings Snapshot Interactive Brokers Group (IBKR) closed out FY 2025 with Q4 total revenue of US$1.7b and basic EPS of US$0.64, alongside net income of US$284m, setting a clear reference point for the year just finished. The company has seen quarterly revenue move from US$1.4b in Q1 2025 to US$1.7b in Q4 2025, while basic EPS has ranged from US$0.49 in Q1 to US$0.64 in Q4, providing a clear view of how the top and bottom line have tracked through the year as you weigh the...